Andrea Lenzi to Prognosis
This is a "connection" page, showing publications Andrea Lenzi has written about Prognosis.
Connection Strength
0.135
-
Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018 03; 6(3):173-185.
Score: 0.033
-
Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis. J Endocrinol Invest. 2018 May; 41(5):591-596.
Score: 0.033
-
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020 10 01; 19(1):164.
Score: 0.010
-
The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence. J Endocrinol Invest. 2019 Jun; 42(6):715-725.
Score: 0.009
-
Gender difference and correlation between sexuality, thyroid hormones, cognitive, and physical functions in elderly fit. J Endocrinol Invest. 2019 Jun; 42(6):699-707.
Score: 0.009
-
Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. J Endocrinol Invest. 2019 May; 42(5):513-520.
Score: 0.009
-
Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. Diabetes Metab Res Rev. 2018 07; 34(5):e2998.
Score: 0.008
-
Effects of an individualized home-based unsupervised aerobic training on body composition and physiological parameters in obese adults are independent of gender. J Endocrinol Invest. 2018 Apr; 41(4):465-473.
Score: 0.008
-
Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest. 2017 Dec; 40(12):1321-1326.
Score: 0.008
-
Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. Am Heart J. 2017 Jul; 189:120-127.
Score: 0.008